CLLS (Cellectis) 1-Year Share Buyback Ratio : -0.50% (As of Mar. 2025 )

View and export this data going back to 2015. Start your Free Trial

What is Cellectis 1-Year Share Buyback Ratio?

Shares Outstanding (EOP) are shares that have been authorized, issued, and purchased by investors and are held by them.

1-Year Share Buyback Ratio measures the proportion of a company's outstanding shares repurchased over the past year, calculated as the percentage change in shares outstanding from the previous year to the current year. A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance. Cellectis's current 1-Year Share Buyback Ratio was -0.50%.

CLLS's 1-Year Share Buyback Ratio is ranked better than
83.72% of 1167 companies
in the Biotechnology industry
Industry Median: -11.2 vs CLLS: -0.50

Competitive Comparison of Cellectis's 1-Year Share Buyback Ratio

For the Biotechnology subindustry, Cellectis's 1-Year Share Buyback Ratio, along with its competitors' market caps and 1-Year Share Buyback Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Cellectis's 1-Year Share Buyback Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Cellectis's 1-Year Share Buyback Ratio distribution charts can be found below:

* The bar in red indicates where Cellectis's 1-Year Share Buyback Ratio falls into.

Save Embed

;

Save Embed

;

Cellectis 1-Year Share Buyback Ratio Calculation

Cellectis's 1-Year Share Buyback Ratio for the quarter that ended in Mar. 2025 is calculated as

1-Year Share Buyback Ratio	=	(Shares Outstanding (EOP) (Mar. 2024 )	-	Shares Outstanding (EOP) (Mar. 2025 ))	/	Shares Outstanding (EOP) (Mar. 2024 )
	=	(71.956	-	72.290)	/	71.956
	=	-0.5%

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Cellectis (NAS:CLLS) 1-Year Share Buyback Ratio Explanation

A positive ratio may indicates share buybacks over the period, while a zero or negative ratio suggests no buybacks or potential share issuance.

Be Aware

Investors usually like share buybacks. But as pointed by Warren Buffett, only if a company buys back shares at the prices below the stock's intrinsic value, it rewards remaining shareholders. If a company buys its overvalued stocks back, it destroys shareholder value.

Cellectis 1-Year Share Buyback Ratio Related Terms

Cellectis Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Cellectis SA (NAS:CLLS) » Definitions » 1-Year Share Buyback Ratio

Comparable Companies

Traded in Other Exchanges

CMVLF:USA 0WA2:UK ALCLS:France ZVA:Germany

Address

8, rue de la Croix Jarry, Paris, FRA, 75013

Website

https://www.cellectis.com

Cellectis SA is a clinical stage biotechnological company, employing the core proprietary technologies to develop products based on gene-editing, with a portfolio of allogeneic Chimeric Antigen Receptor T-cells, or UCART, product candidates in the field of immuno-oncology and gene-edited hematopoietic stem and progenitor cells, or HSPC product candidates in other therapeutic indications.